Figure 1(a) shows that FCGR3A expression was significantly higher in most types of cancer, including lower-grade glioma (LGG). To provide a more comprehensive evaluation of FCGR3A expression in cancers, we used TIMER database to compare FCGR3A expression in tumors and adjacent normal tissues. Similarly, FCGR3A expression was elevated in many cancers (Figure 1(b)). Here, FCGR3A is linked to central nervous system cancer.